Structure-based design and discovery of potent and selective KDM5 inhibitors

被引：39

作者：

Nie, Zhe ^{[1
]}

Shi, Lihong ^{[1
]}

Lai, Chon ^{[1
]}

O'Connell, Shawn M. ^{[1
,3
]}

Xu, Jiangchun ^{[1
]}

Stansfield, Ryan K. ^{[1
,4
]}

Hosfield, David J. ^{[2
]}

Veal, James M. ^{[1
,4
]}

Stafford, Jeffrey A. ^{[1
,4
]}

机构：

[1] Celgene Corp, 10300 Campus Point Dr,Suite 100, San Diego, CA 92121 USA

[2] Univ Chicago, Ben May Dept Canc Res, 929 East 57th St, Chicago, IL 60637 USA

[3] Pfizer Inc, Groton, CT 06340 USA

[4] Jecure Therapeut, San Diego, CA USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2018年 / 28卷 / 09期

关键词：

Epigenetics; Histone lysine demethylase; KDM5; Tri-methylated H3K4; Structure-based design; HISTONE DEMETHYLASES; CANCER; CELLS; MELANOMA; TARGETS;

D O I：

10.1016/j.bmcl.2018.03.083

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Histone lysine demethylases (KDMs) play a key role in epigenetic regulation and KDM5A and KDM5B have been identified as potential anti-cancer drug targets. Using structural information from known KDM4 and KDM5 inhibitors, a potent series of pyrazolylpyridines was designed. Structure-activity relationship (SAR) exploration resulted in the identification of compound 33, an orally available, potent inhibitor of KDM5A/5B with promising selectivity. Potent cellular inhibition as measured by levels of tri-methylated H3K4 was demonstrated with compound 33 in the breast cancer cell line ZR-75-1. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：1490 / 1494

页数：5

共 50 条

[1] Identification of potent, selective KDM5 inhibitors
Gehling, Victor S.
Bellon, Steven F.
Harmange, Jean-Christophe
LeBlanc, Yves
Poy, Florence
Odate, Shobu
Buker, Shane
Lan, Fei
Arora, Shilpi
Williamson, Kaylyn E.
Sandy, Peter
Cummings, Richard T.
Bailey, Christopher M.
Bergeron, Louise
Mao, Weifeng
Gustafson, Amy
Liu, Yichin
VanderPorten, Erica
Audia, James E.
Trojer, Patrick
Albrecht, Brian K.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (17) : 4350 - 4354
[2] At Long Last Potent and Selective KDM5 Inhibitors
Rotili, Dante
Mattevi, Andrea
CELL CHEMICAL BIOLOGY, 2016, 23 (07): : 749 - 751
[3] From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
Liang, Jun
Labadie, Sharada
Zhang, Birong
Ortwine, Daniel F.
Patel, Snahel
Vinogradova, Maia
Kiefer, James R.
Mauer, Till
Gehling, Victor S.
Harmange, Jean-Christophe
Cummings, Richard
Lai, Tommy
Liao, Jiangpeng
Zheng, Xiaoping
Liu, Yichin
Gustafson, Amy
Van der Porten, Erica
Mao, Weifeng
Liederer, Bianca M.
Deshmukh, Gauri
An, Le
Ran, Yingqing
Classon, Marie
Trojer, Patrick
Dragovich, Peter S.
Murray, Lesley
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (13) : 2974 - 2981
[4] Structure-Based Design of Potent and Selective Inhibitors of Pyruvate Carboxylase
Schneider, Nicholas
Burkett, Daniel
Wyatt, Brittney
Mews, Mallory
Bautista, Anson
Engel, Ryan
Dockendorff, Chris
Donaldson, William
St Maurice, Martin
PROTEIN SCIENCE, 2021, 30 : 141 - 141
[5] Design, Synthesis and Characterization of Covalent KDM5 Inhibitors
Vazquez-Rodriguez, Saleta
Wright, Miranda
Rogers, Catherine M.
Cribbs, Adam P.
Velupillai, Srikannathasan
Philpott, Martin
Lee, Henry
Dunford, James E.
Huber, Kilian V. M.
Robers, Matthew B.
Vasta, James D.
Thezenas, Marie-Laetitia
Bonham, Sarah
Kessler, Benedikt
Bennett, James
Fedorov, Oleg
Raynaud, Florence
Donovan, Adam
Blagg, Julian
Bavetsias, Vassilios
Oppermann, Udo
Bountra, Chas
Kawamura, Akane
Brennan, Paul E.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2019, 58 (02) : 515 - 519
[6] From a novel HTS hit to a series of potent, selective, orally bioavailable KDM5 inhibitors: A success story utilizing structure-and property-based design
Liang, Jun
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[7] Structure-Based Design of Potent and Selective CK1γ Inhibitors
Huang, Hongbing
Acquaviva, Lisa
Berry, Virginia
Bregman, Howard
Chakka, Nagasree
O'Connor, Anne
DiMauro, Erin F.
Dovey, Jennifer
Epstein, Oleg
Grubinska, Barbara
Goldstein, Jon
Gunaydin, Hakan
Hua, Zihao
Huang, Xin
Huang, Liyue
Human, Jason
Long, Alex
Newcomb, John
Patel, Vinod F.
Saffran, Doug
Serafino, Randy
Schneider, Steve
Strathdee, Craig
Tang, Jin
Turci, Susan
White, Ryan
Yu, Violeta
Zhao, Huilin
Wilson, Cindy
Martin, Matthew W.
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (12): : 1059 - 1064
[8] Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation
Wu, Shuang
Liao, Min
Li, Minxiong
Sun, Mingming
Xi, Ning
Zeng, Youlin
RSC MEDICINAL CHEMISTRY, 2022, 13 (10): : 1246 - 1264
[9] Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors
Bhide, Rajeev S.
Keon, Alec
Weigelt, Carolyn
Sack, John S.
Schmidt, Robert J.
Lin, Shuqun
Xiao, Hai-Yun
Spergel, Steven H.
Kempson, James
Pitts, William J.
Carman, Julie
Poss, Michael A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (21) : 4908 - 4913
[10] Structure-based drug design of selective 5′-nucleotidases inhibitors
Pachl, P.
Brynda, J.
Rosenberg, I.
Fabry, M.
Rezacova, P.
FEBS JOURNAL, 2009, 276 : 159 - 159

← 1 2 3 4 5 →